共 50 条
- [1] Five-Year Outcomes From a Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S33 - S34
- [2] Stereotactic Body Radiation Therapy for Intermediate-risk Organ-confined Prostate Cancer: Interim Toxicity and Quality of Life Outcomes From a Multi-institutional Study [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S148 - S148
- [3] Long-Term Outcomes of Stereotactic Body Radiation Therapy for Low and Intermediate-Risk Prostate Adenocarcinoma: A Multi-Institutional Consortium Study [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S106 - S106
- [4] Hypofractionated Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: A Multi-institutional Phase 2 Analysis [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E197 - E198
- [5] Outcomes of Stereotactic Body Radiation Therapy Delivered by Gantry-Based Linear Accelerators for Low and Intermediate-Risk Prostate Adenocarcinoma: A Multi-institutional Study [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S107 - S107
- [8] Five-year Biochemical Control Rates for Stereotactic Body Radiation Therapy for Organ-confined Prostate Cancer: A Multi-institutional Pooled Analysis [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S147 - S148
- [9] Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer [J]. RADIATION ONCOLOGY, 2013, 8
- [10] Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer [J]. Radiation Oncology, 8